Product Name: EGFR Antibody [H9B4]
Species Reactivity: Human
Tested Applications: IP, WB
Applications: IP: 1-2µg/500ug protein lysateWB: 0.5-1 ug/mlTitration of the antibody may be required for optimal performance.1. This antibody reacts with a cytoplasmic domain of EGFR.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Purified EGFR from A431 cells was used as the immunogen for this antibody. (1)
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 357263-13-9
Product: BMS-378806
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
Accession NO.:
Protein Ino:
Official Symbol: EGF R
Geneid: 1956
Background: Epidermal Growth Factor Receptor is a type I receptor tyrosine kinase, referred to as EGFR, ErbB1 and HER1. When EGFR is activated by one of its ligands, it dimerizes. It can form a homodimer, heterodimers with other ErbB family members, or even a cluster of EGFRs. Activation stimulates EGFRs intracellular kinase activity. Autophosphorylation of tyrosine residues in the C-terminal domain of EGFR leads to association with proteins with phosphotyrosine-binding domains which then signal the initiation of signal transduction cascades including the JNK, MAPK, AKT, and possibly Nf-KB, pathways. Overexpression of EGFR is the cause of some types of cancer, including lung and colon cancer. It has also been linked to psoriasis, eczema and atherosclerosis, although poorly defined. Monoclonal antibody to EGFR can be used to block the extracellular ligand binding domain, therebye blocking tyrosine kinase activation and subsequent signal transduction.
PubMed ID:http://aac.asm.org/content/39/7/1425.abstract
